Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
Azitra secured U.S. Patent No. 12,606,610 B2 covering its lead candidate ATR-12, an engineered microbe designed to treat Netherton syndrome. The patent protects compositions and methods for using LEKTI-expressing recombinant microbes, bolstering the company's intellectual property portfolio around precision dermatology.
Key figures
- Drug Name
- ATR-12
- Phase Of Trial
- Phase 1b
- Microbial library size
- 1,500
- Addressable patient count global
- 20,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.